Compare Citius Pharmaceuticals Inc (CTXR) vs GameStop Corp. (GME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs GameStop Corp. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while GameStop Corp. trades at $26.45 (market cap $12.75B). The key difference: GameStop Corp. is far larger — about 936.1× Citius Pharmaceuticals Inc's market cap, and GameStop Corp. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and GameStop Corp. for 62 Days on average.
| CTXR | GME | |
|---|---|---|
Market Cap | $13.62M | $12.75B |
Volume | 132,438 | 13,026,993 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $26.53 |
52-Week Low | $0.48 | $17.87 |
Typical Hold Time | 17 Days | 62 Days |
Enterprise Value | $3.79M | $12.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
GameStop (GME) trades at $26.37, up 7.28% in 24 hours, with a bullish technical signal and strong insider buying by CEO Ryan Cohen. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, though revenue declined to $3.82 billion. Valuation ratios include a P/E of 16.63 and P/S of 4.22, while analyst consensus remains mixed with 16.67% buy ratings.
The outlook hinges on sustained profitability and strategic shifts, but risks include revenue volatility and competitive pressures. Insider confidence provides near-term support, yet the stock faces headwinds from cautious Wall Street sentiment and execution challenges in a declining physical retail environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →
